If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
165
results.
Updated on
14/07/2025 [06:56:00]
Results 150 to 165 of 165
Absstract of: US2025152817A1
Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.
Absstract of: US2025152673A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Absstract of: US2025152049A1
The present invention relates to a glucose diffusion control layer solution for a continuous blood glucose-measuring biosensor, a glucose diffusion control layer for a continuous blood glucose-measuring biosensor, comprising the same, and a continuous blood glucose-measuring biosensor comprising the same. More specifically, the present invention relates to: a glucose diffusion control layer solution for a continuous blood glucose-measuring biosensor, in which, by using only a substance of which biocompatibility has been verified, stability can be ensured even when injected into the human body, and glucose permeability and water absorbance can be controlled; a glucose diffusion control layer for a continuous blood glucose-measuring biosensor, comprising the same; and a continuous blood glucose-measuring biosensor comprising the same.
Absstract of: US2025152045A1
A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a smartwatch interior houses the VCSEL laser. The smartwatch includes one or more of a display, an optical sensor, one or more electrodes, SIM card slot, speaker, microphone, charging pins, and a band.
Absstract of: US2025152048A1
The present disclosure discloses to a health analysis method for blood glucose management, a health analysis apparatus for blood glucose management, an electronic device and a storage medium. The health analysis method includes: obtaining a plurality of blood glucose data of a user during a detection time period, wherein the plurality of blood glucose data include a current blood glucose value detected at a current moment; determining a time in range ratio of the user according to the plurality of blood glucose data and a glucose standard range; predicting a time when a blood glucose value of the user meets the glucose standard range and a time when the time in range ratio meets a qualified condition according to the current blood glucose value and the time in range ratio; and analyzing predicted results to provide a blood glucose prediction curve to the user.
Absstract of: US2025152046A1
The blood glucose detector (BGD) is placed on user's wrist, ear, nose, or other skin surface, at a NIR light infiltration location to detect arterial blood flow. Earlier-obtained baseline BG data is obtained via BGD and conventionally-obtained BG data. The user-wearable housing or body-mounted BGD system includes processor, memory, and NIR transmitter/sensor. BG baseline data is stored in memory. The NIR transmitter/sensor disposed on infiltration location. In detection, transmitter generates light in predetermined narrow band within NIR range 1350-1800 nm. Sensor detects reflected light from arterial BG as then-detected BG signal. Memory stores a subcutaneous interference factor (SIF) contributory value for NIR narrow band. Onboard processor (or smart phone APP) correlates the detected BG signal with the baseline as modified by the SIF value and generates displayable BG level to user via user-wearable housing or the user interface display on the smart phone as connected to body-mounted BGD system.
Absstract of: US2025152107A1
A diabetes risk detection method, an electronic device, and a system are disclosed and are applied to the field of terminal technologies, to resolve a problem in the conventional technology that an obtained diabetes risk detection result is inaccurate when time for collecting a photoplethysmography signal is short. The method includes: obtaining first data and second data, where the first data includes a photoplethysmography (PPG) signal obtained via a PPG sensor, and the second data includes one or more of the following: diet data, exercise data, physical symptom data, drug use data, sleep data, or emotion data; determining a diabetes risk detection result based on the first data and the second data; and outputting the diabetes risk detection result to prompt a user with a health status.
Absstract of: US2025152060A1
Method and apparatus for optimizing analyte sensor calibration including receiving a current blood glucose measurement, retrieving a time information for an upcoming scheduled calibration event for calibrating an analyte sensor, determining temporal proximity between the current blood glucose measurement and the retrieved time information for the upcoming calibration event, initiating a calibration routine to calibrate the analyte sensor when the determined temporal proximity is within a predetermined time period, and overriding the upcoming scheduled calibration event using the current blood glucose measurement are provided.
Absstract of: US2025152058A1
Embodiments of the invention provide compositions useful in implantable devices such as analyte sensors as well as methods for making and using such compositions and devices. In typical embodiments of the invention, the device is a glucose sensor comprising a polymeric composition disposed on a flexible assembly within the sensor that includes amounts of one or more immunosuppressant agents designed to provide such sensors with improved material properties such as enhanced biocompatibility.
Absstract of: US2025152053A1
A glucose measurement device comprising a light emitting device comprising an SWIR phosphor having emission wavelengths in the range of 1600-2200 nm, the SWIR phosphor comprising a structurally disordered garnet material, a sensitizer ion, and at least one rare earth emitter ion, and a infrared light detector arranged to detect the intensity of short wavelength infrared light emitted by the light emitting device and reflected by a sample. The emission spectra provided by the light emitting device having a high temperature stability at infrared absorption minima and maxima wavelengths of glucose in tissue.
Absstract of: US2025152103A1
Provided is a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a Separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: US2025152054A1
Various embodiments of a user-wearable device can comprise a frame configured to mount on a user. The device can include a display attached to the frame and configured to direct virtual images to an eye of the user. The device can also include a light source configured to provide polarized light to the eye of the user and that the polarized light is configured to reflect from the eye of the user. The device can further include a light analyzer configured to determine a polarization angle rotation of the reflected light from the eye of the user such that a glucose level of the user can be determined based at least in part on the polarization angle rotation of the reflected light.
Absstract of: US2025152051A1
This application provides a blood glucose assessment method, an electronic device, and a computer-readable storage medium. The method is applied to a wearable device, and includes: collecting vital sign data of a user in a first cycle of blood glucose assessment; performing blood glucose assessment on the user based on valid vital sign data in the vital sign data, to obtain a blood glucose assessment result corresponding to the first cycle; displaying the blood glucose assessment result corresponding to the first cycle; and automatically starting a next cycle of the blood glucose assessment. According to the technical solutions of this application, blood glucose assessment can be periodically and automatically performed, helping reduce operation complexity for the user.
Absstract of: WO2025099153A1
The invention concerns a method for determining a substance concentration in a sample comprising liquid containing particles, in particular glucose in blood, wherein a refractive index of the liquid is dependent on a concentration of the substance dissolved therein and a density of particles in the liquid is substantially constant. The method comprises obtaining a PPG first signal during a first time period and estimating at last a portion of a noise spectrum from the first obtained signal in particular the frequency domain. At least a portion of the noise spectrum is used to derive the substance concentration or a change in the substance concentration.
Nº publicación: US2025152809A1 15/05/2025
Applicant:
DEKA PRODUCTS LP [US]
DEKA Products Limited Partnership
Absstract of: US2025152809A1
A medical system includes an input assembly for receiving one or more user inputs. The input assembly includes at least one slider assembly for providing an input signal. Processing logic receives the input signal from the input assembly and provides a first output signal and a second output signal. A display assembly is configured to receive, at least in part, the first output signal from the processing logic and render information viewable by the user. The second output signal is provided to one or more medical system components. The information rendered on the display assembly may be manipulatable by the user and at least a portion of the information rendered may be magnified.
BOPI
Electronic site
